aldevron Profile Banner
Aldevron Profile
Aldevron

@aldevron

Followers
899
Following
220
Media
555
Statuses
1K

We serve the biotech industry by manufacturing high quality biologics, impacting lives worldwide. 🔸Plasmid DNA 🔸mRNA 🔸Proteins Discovery➡Clinical➡Commercial

Fargo, ND
Joined September 2010
Don't wanna be here? Send us removal request.
@aldevron
Aldevron
1 year
#mRNA developers face challenges to meet standards for #clinical applications. In our webinar, Developing Processes for Successful Clinical-Grade mRNA Manufacturing, our experts discuss the importance of process development to meet those standards.
Tweet card summary image
aldevron.com
Process development for clinical applications is a challenge for mRNA developers but is highly important for producing quality mRNA and saRNA.
5
0
1
@aldevron
Aldevron
1 year
Non-viral modalities in dealing with #genetherapy and #celltherapy are becoming a larger consideration for #therapeutics developers, as Pat Paez discusses in a presentation from #BiotechWeekBoston
Tweet card summary image
aldevron.com
An evolution in non-viral manufacturing modalities is starting to have an impact on biotech workflows, with novel approaches coming into play.
2
0
0
@aldevron
Aldevron
1 year
ICYMI Defining quality attributes and analytical testing procedures. Those are the next steps as mRNA-based medicines move toward #clinical development stages. Nate Spangler discusses that in his latest blog post. #mRNA
Tweet card summary image
aldevron.com
As potential for mRNA treatments grows, defining quality attributes and analytical testing procedures becomes an important part of development processes.
0
0
0
@aldevron
Aldevron
1 year
Advancement and evolution. Alex Liu discusses how they are affecting the potential for #celltherapy and #genetherapy as he looks forward to continuing the journey of transformative therapies. https://t.co/tib63yimUp
0
0
0
@aldevron
Aldevron
1 year
#bipProcessUK's annual meeting starts Tuesday in Liverpool! Take the opportunity to learn about how Aldevron can assist you in your #celltherapy and #genetherapy programs at booth 30 and see what we have to offer https://t.co/Qe5jdfUEFq
0
0
0
@aldevron
Aldevron
1 year
Defining quality attributes and analytical testing procedures. Those are the next steps as mRNA-based medicines move toward #clinical development stages. Nate Spangler discusses that in his latest blog post. #mRNA
Tweet card summary image
aldevron.com
As potential for mRNA treatments grows, defining quality attributes and analytical testing procedures becomes an important part of development processes.
0
0
0
@aldevron
Aldevron
1 year
Meet us in Liverpool for the #bipProcessUK annual meeting to learn about how Aldevron can assist you in your #celltherapy and #genetherapy programs. Visit with Stuart King and Clare Whitewoods at booth 30 and see what we have to offer https://t.co/LVg8QROF1l
0
0
0
@aldevron
Aldevron
1 year
#Capping efficiency is one of the concerns as #mRNA becomes widely used, with several options now available that can improve that efficiency, with RNA #polymerase being a key factor for consideration https://t.co/uGKoMDRzJp
0
0
0
@aldevron
Aldevron
1 year
An exciting agenda is coming up @mrnaconference in Boston, Nov 12-14. Meet Aldevron’s experts to discuss the latest in #mRNA and what the future holds. Don’t miss Tao Lu’s presentation on mRNA manufacturing strategies on Nov 14 #mRNA2024 https://t.co/G44xiY5skn
0
0
0
@aldevron
Aldevron
1 year
ICYMI #CRISPR offers great potential in advanced therapies. In his post, A Biological Hijack, Patrick Paez discusses his whitepaper, Next-generation CRISPR Approaches, and how new CRISPR approaches can activate #DNA repair mechanisms https://t.co/L71bJoQAja
0
0
0
@aldevron
Aldevron
1 year
#CRISPR offers great potential in advanced therapies. In his post, A Biological Hijack, Patrick Paez discusses his whitepaper, Next-generation CRISPR Approaches, and how new CRISPR approaches can activate #DNA repair mechanisms. https://t.co/OgcDYKfBcI
0
0
0
@aldevron
Aldevron
1 year
ICYMI #Nonviral #gene delivery expression levels can be boosted by Nanoplasmid™ vectors. In his post, Tyler Kozisek explains why and offers 8 different reporter constructs that #therapeutic developers can test. https://t.co/4rSN0dh91E
0
0
0
@aldevron
Aldevron
1 year
#Nonviral #gene delivery expression levels can be boosted by Nanoplasmid™ vectors. In his post, Tyler Kozisek explains why and offers 8 different reporter constructs that #therapeutic developers can test. https://t.co/bh26MWt8SY
0
0
0
@aldevron
Aldevron
1 year
ICYMI #mRNA drug product manufacturing requires high efficiency and reducing impurities such as #dsRNA. Learn more in our #webinar, Streamlining the Path from Discovery to Patient: Simpler RNA Manufacturing #HiCap #polymerase
Tweet card summary image
aldevron.com
In the ever-changing mRNA vaccine and therapeutics field, manufacturing of the final drug product is critical. To show how Aldevron works to continuously improve on that process, we hosted the...
0
0
0
@aldevron
Aldevron
1 year
Early in your clinical programs? Aldevron’s new small-scale cGMP service for up to 500mg of plasmid DNA deliverables helps you advance your work. Trust your pDNA partner has been providing clients with the highest quality products and services since 1998. https://t.co/pMiqGEGP6o
0
0
0
@aldevron
Aldevron
1 year
ICYMI Impurities in #mRNA, such as #dsRNA, can lead to adverse effects in #therapeutics. Purification can be costly and time-consuming, but there is an alternative in engineered #enzymes, as Kyle Studey points out #polymerase https://t.co/QkhqV0Qj3y
0
0
0
@aldevron
Aldevron
1 year
#mRNA drug product manufacturing requires high efficiency and reducing impurities such as #dsRNA. Learn more in our #webinar, Streamlining the Path from Discovery to Patient: Simpler RNA Manufacturing #HiCap #polymerase
Tweet card summary image
aldevron.com
In the ever-changing mRNA vaccine and therapeutics field, manufacturing of the final drug product is critical. To show how Aldevron works to continuously improve on that process, we hosted the...
0
0
0
@aldevron
Aldevron
1 year
Impurities in #mRNA, such as #dsRNA, can lead to adverse effects in #therapeutics. Purification can be costly and time-consuming, but there is an alternative in engineered #enzymes, as Kyle Studey points out #polymerase https://t.co/4E5XA1S5FD
0
0
0
@aldevron
Aldevron
1 year
ICYMI Making manufacturing process decisions early in a therapeutic’s discovery stage can be a critical factor to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now #atmp #therapeutics https://t.co/GXKh228LZo
0
0
0
@aldevron
Aldevron
1 year
Making manufacturing process decisions early in a therapeutic’s discovery stage can be a critical factor to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now #atmp #therapeutics https://t.co/4cO2vAy3rl
0
0
0